Literature DB >> 15196260

The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents.

A Stray-Pedersen1, T Jónsson, A Heiberg, C R Lindman, E Widing, I S Aaberge, A L Borresen-Dale, T G Abrahamsen.   

Abstract

Eleven Norwegian patients (aged 2-33 years, seven males and four females) with Ataxia-telangiectasia (A-T) and their parents were investigated. Five of the patients were homozygous for the same ATM mutation, 3245delATCinsTGAT, a Norwegian founder mutation. They had the lowest IgG2 levels; mean (95% confidence interval) 0.23 (0.05-0.41) g/l versus 0.91 (0.58-1.26) g/l in the other patients (P = 0.002). Among the 11 A-T patients, six had IgG2 deficiency, six had IgA deficiency (three in combination with IgG2 deficiency) and seven had low/undetectable IgE values. All patients had very low levels of antibodies to Streptococcus pneumoniae 0.9 (0.4-1.4) U/ml, while normal levels were found in their parents 11.1 (8.7-13.4) U/ml (P < 0.001). A positive linear relationship between pneumococcal antibodies and IgG2 (r = 0.85, P = 0.001) was found in the patients. Six of 11 had diphtheria antibodies and 7 of 11 tetanus antibodies after childhood vaccinations, while 4 of 7 Hemophilus influenzae type b (Hib) vaccinated patients had protective antibodies. Ten patients had low B cell (CD19+) counts, while six had low T cell (CD3+) counts. Of the T cell subpopulations, 11 had low CD4+ cell counts, six had reduced CD8+ cell counts, and four had an increased portion of double negative (CD3+/CD4-/CD8-) gamma delta T cells. Of the 22 parents (aged 23-64 years) 12 were heterozygous for the ATM founder mutation. Abnormalities in immunoglobulin levels and/or lymphocyte subpopulations were also observed in these carriers, with no correlation to a special ATM genotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196260      PMCID: PMC1809075          DOI: 10.1111/j.1365-2249.2004.02492.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  [Ataxia-telangiectasia surveyed in Sweden].

Authors:  A Lähdesmäki; K Arinbjarnarson; J Arvidsson; M el Segaier; A Fasth; E Fernell; D Gustafsson; V A Oxelius; K Risberg; J Yuen; P Zetterlund; M von Zweigbergk; I Ahsgren; L Hammarström
Journal:  Lakartidningen       Date:  2000-10-04

2.  Human antibody response to a pneumococcal vaccine in SCID-PBL-hu mice and simultaneously vaccinated human cell donors.

Authors:  I S Aaberge; T E Steinsvik; E C Groeng; R B Leikvold; M Løvik
Journal:  Clin Exp Immunol       Date:  1996-07       Impact factor: 4.330

3.  Immunoglobulins in ataxia-telangiectasia: evidence for IgG4 and IgA2 subclass deficiencies.

Authors:  L Rivat-Peran; D Buriot; J P Salier; C Rivat; S M Dumitresco; C Griscelli
Journal:  Clin Immunol Immunopathol       Date:  1981-07

4.  IgE in ataxia-telangiectasia and family members.

Authors:  D Biggar; N Lapointe; K Ishizaka; H Meuwissen; R A Good; D Frommel
Journal:  Lancet       Date:  1970-11-21       Impact factor: 79.321

5.  Genotype-phenotype relationships in ataxia-telangiectasia and variants.

Authors:  S Gilad; L Chessa; R Khosravi; P Russell; Y Galanty; M Piane; R A Gatti; T J Jorgensen; Y Shiloh; A Bar-Shira
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

6.  Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients.

Authors:  A Li; M Swift
Journal:  Am J Med Genet       Date:  2000-05-29

7.  Relative increase of T cells expressing the gamma/delta rather than the alpha/beta receptor in ataxia-telangiectasia.

Authors:  M Carbonari; M Cherchi; R Paganelli; G Giannini; E Galli; C Gaetano; C Papetti; M Fiorilli
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

8.  Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines.

Authors:  T Nordøy; A Husebekk; I S Aaberge; P A Jenum; H H Samdal; L B Flugsrud; A C Kristoffersen; H Holte; S Kvaløy; A Kolstad
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

9.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

Authors:  K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

10.  Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia.

Authors:  Antonello Giovannetti; Francesca Mazzetta; Elisabetta Caprini; Alessandro Aiuti; Marco Marziali; Marina Pierdominici; Andrea Cossarizza; Luciana Chessa; Enrico Scala; Isabella Quinti; Giandomenico Russo; Massimo Fiorilli
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

View more
  8 in total

1.  Exclusion/confirmation of ataxia-telangiectasia via cell-cycle testing.

Authors:  Tilman Heinrich; Carolin Prowald; Richard Friedl; Benni Gottwald; Reinhard Kalb; Kornelia Neveling; Sabine Herterich; Holger Hoehn; Detlev Schindler
Journal:  Eur J Pediatr       Date:  2006-01-13       Impact factor: 3.183

2.  Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia.

Authors:  A Stray-Pedersen; I S Aaberge; A Früh; T G Abrahamsen
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

3.  Cutaneous and systemic granulomatosis in ataxia-telangiectasia: a clinico-pathological study.

Authors:  Aleksandra Szczawińska-Popłonyk; Katarzyna Olejniczak; Katarzyna Tąpolska-Jóźwiak; Maciej Boruczkowski; Katarzyna Jończyk-Potoczna; Jadwiga Małdyk; Anna Bręborowicz
Journal:  Postepy Dermatol Alergol       Date:  2020-11-07       Impact factor: 1.837

4.  Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene.

Authors:  E R Staples; E M McDermott; A Reiman; P J Byrd; S Ritchie; A M R Taylor; E G Davies
Journal:  Clin Exp Immunol       Date:  2008-05-26       Impact factor: 4.330

5.  Genetic Risk Variants for Class Switching Recombination Defects in Ataxia-Telangiectasia Patients.

Authors:  Parisa Amirifar; Mahya Mehrmohamadi; Mohammad Reza Ranjouri; Seyed Mohammad Akrami; Nima Rezaei; Ali Saberi; Reza Yazdani; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2021-10-10       Impact factor: 8.542

6.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

7.  Placental transfer of maternally-derived IgA precludes the use of guthrie card eluates as a screening tool for primary immunodeficiency diseases.

Authors:  Stephan Borte; Magdalena Janzi; Qiang Pan-Hammarström; Ulrika von Döbeln; Lennart Nordvall; Jacek Winiarski; Anders Fasth; Lennart Hammarström
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

8.  Second-Tier Next Generation Sequencing Integrated in Nationwide Newborn Screening Provides Rapid Molecular Diagnostics of Severe Combined Immunodeficiency.

Authors:  Janne Strand; Kiran Aftab Gul; Hans Christian Erichsen; Emma Lundman; Mona C Berge; Anette K Trømborg; Linda K Sørgjerd; Mari Ytre-Arne; Silje Hogner; Ruth Halsne; Hege Junita Gaup; Liv T Osnes; Grete A B Kro; Hanne S Sorte; Lars Mørkrid; Alexander D Rowe; Trine Tangeraas; Jens V Jørgensen; Charlotte Alme; Trude E H Bjørndalen; Arild E Rønnestad; Astri M Lang; Terje Rootwelt; Jochen Buechner; Torstein Øverland; Tore G Abrahamsen; Rolf D Pettersen; Asbjørg Stray-Pedersen
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.